Document is current
Any future updates will be listed below
-
Authors
Sakata, Asuka https://orcid.org/0000-0001-7144-001X
Tatsumi, Kohei
Matsumoto, Naoki
Mackman, Nigel
Harada, Suguru
Kawasaki, Ryohei
Okuyama-Nishida, Yukiko
Soeda, Tetsuhiro
Nogami, Keiji
Shima, Midori
-
Funding
Funding for this research was provided by:
F. Hoffmann-La Roche Ltd | Chugai Pharmaceutical
- License Information
-
More Information
Article History
Received: 29 August 2024
Accepted: 26 February 2025
First Online: 8 March 2025
Competing interests
: This study was funded by Chugai Pharmaceutical. The authors declare the following competing interests: A.S., K.T., Naoki M., S.H., R.K., Y.N., T.S., K.N., and M.S.: Members of the Medicinal Biology of Thrombosis and Haemostasis established by Nara Medical University and Chugai Pharmaceutical Co., Ltd. Naoki M., S.H., R.K., Y.N., and T.S.: Employees of Chugai Pharmaceutical Co., Ltd. Naoki M., S.H. and R.K.: Ownership of stock by Chugai Pharmaceutical Co., Ltd. M.S.: Patents for inventions related to products of Chugai Pharmaceutical Co., Ltd. K.T.: Grants or research support from the Japan Blood Products Organization, the Mother and Child Health Foundation and Novo Nordisk Pharma. M.S.: Takeda Pharmaceutical Co., Ltd., and CSL Behring; honoraria or consultation fees from Chugai Pharmaceutical Co., Ltd.; speaker bureau from Chugai Pharmaceutical Co., Ltd.; CSL Behring, Sanofi, Bayer, Novo Nordisk Pharma, Takeda Pharmaceutical Co., Ltd., Pfizer, and Fujimoto Seiyaku Corp. K.N.: Representative of Medicinal Biology of Thrombosis and Haemostasis collaborative research laboratory; research support from Chugai Pharmaceutical Co., Ltd.; grants or research support from Chugai Pharmaceutical Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; KM Biologics Co., Ltd.; Sanofi Co., Ltd.; Novo Nordisk Pharma Co., Ltd.; Bayer Co., Ltd.; AbbVie GK LLC; Janssen Pharmaceutical K.K. Co., Ltd.; honouraria or consultation fees from Chugai Pharmaceutical Co., Ltd.; Sanofi Co., Ltd.; and CSL Behring.
